Wogonoside: Pharmacology, molecular targets and therapeutic potential.
TL;DR
Current advances in the chemical analysis, pharmacokinetics, biotransformation, molecular pharmacology, and disease-specific actions of wogonoside are summarized, and key challenges for future development are discussed, including variable bioavailability, metabolite contribution, target specificity, pharmacokinetic-pharmacodynamic relationships, and clinical translation.
Abstract
Wogonoside, a major flavone 7-O-glucuronide from Scutellaria baicalensis Georgi, has long been used as a quality-control marker for Scutellariae Radix and related traditional herbal formulations. Emerging evidence suggests that wogonoside is not merely an analytical marker or an inactive glucuronide, but a pharmacologically active constituent and potential precursor of bioactive metabolites. In preclinical models, it exhibits anti-inflammatory, antioxidant, anti-angiogenic, anti-fibrotic, antitumor, cardioprotective, neuroprotective, and renoprotective activities. These effects are associated with the regulation of key signaling networks involved in inflammation, oxidative stress, inflammasome activation, autophagy, angiogenesis, fibrosis, and regulated cell death. Representative mechanisms include modulation of TLR4/NF-κB/NLRP3, Nrf2/HO-1, PI3K/AKT/mTOR, AMPK/mTOR, Wnt/β-catenin, Hedgehog/SMO/Gli1, and ferroptosis-related SLC7A11/GPX4 signaling. Recent target-validation studies have identified several candidate molecular targets, including SMO, NF-κB p65, HNF4α, NEK7, GPX4, TLR4, and CD39. However, the strength of evidence varies, and direct target engagement remains to be confirmed for many of these proteins. Pharmacokinetic studies reveal complex disposition characteristics, including intestinal microbial deglycosylation to wogonin, intestinal and hepatic re-glucuronidation, transporter-mediated efflux, enterohepatic or enteric recycling, and frequent multiple-peak plasma profiles. These properties support the value of wogonoside as both a quality-control marker and a dynamic exposure-related marker in Scutellaria-containing preparations. This review summarizes current advances in the chemical analysis, pharmacokinetics, biotransformation, molecular pharmacology, and disease-specific actions of wogonoside, and discusses key challenges for future development, including variable bioavailability, metabolite contribution, target specificity, pharmacokinetic-pharmacodynamic relationships, and clinical translation.